NCT04683003RECRUITINGIRB Ready

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Sponsored by Takeda

Quick Self-Assessment

See if you qualify and express your interest

Preparing your pre-screening questions...
๐Ÿ“Š
0 of 77 participants interested
0% interest

Express Your Interest Today

Interested in learning more? Complete the form below.

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Advance Medical Science

    Contribute to groundbreaking research

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel (varies by study)

  • Help Others

    Benefit future patients

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3In-person assessment if eligible
  4. 4Begin participation

About This Study

Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can also occur.

Who Can Participate

Inclusion Criteria

Participants who have completed TAK-755 Phase 3 pivotal Study 281102 (NCT03393975) in the prophylactic cohort and who meet all of the following criteria are eligible for this study:
Participants or legally authorized representative has provided signed informed consent \>=18 years of age and/or assent form \<18 years of age.
Participant 0 to 70 years of age at the time of screening of the 281102 (NCT03393975) study.
Participant has been diagnosed with severe congenital ADAMTS-13 deficiency.
Participant does not display any severe thrombotic thrombocytopenic purpura (TTP) signs (platelet count \<100,000/ microliter (mcL) and elevation of lactate dehydrogenase (LDH) greater than (\>) 2 ร— ULN at screening (prophylactic cohort only).
Participants \>=16 years of age must have a Karnofsky score \>= 70% and participants \<16 years of age must have a Lansky score \>=80%.
If female of childbearing potential, participant presents with a negative serum or urine pr

โ“ Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility during the screening process.

Study Details

๐Ÿ“‹

Study Type

INTERVENTIONAL

๐Ÿ‘ฅ

Target Enrollment

77 participants

โšง

Gender

ALL

๐Ÿข

Sponsor

Takeda

Study Locations

Choose your preferred location or select flexible during enrollment

RECRUITING

Atlanta

Georgia

Location available
View Atlanta location page
RECRUITING

Buffalo

New York

Location available
View Buffalo location page
RECRUITING

Durham

North Carolina

Location available
View Durham location page
RECRUITING

Dublin

Ohio

Location available
View Dublin location page
RECRUITING

Oklahoma City

Oklahoma

Location available
View Oklahoma City location page

Frequently Asked Questions

Q:What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Q:Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Q:Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Q:Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

Q:How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Still have questions? Our study coordinators are here to help.

Ready to Make a Difference?

Express your interest in this groundbreaking clinical trial

๐Ÿ”’ Secure ยท ๐Ÿฅ Expert Care

Looking for Thrombotic Thrombocytopenic Purpura Treatment in Atlanta?

Join others in Georgia exploring innovative treatment options through clinical research

Thrombotic Thrombocytopenic Purpura Treatment Options in Atlanta, Georgia

If you're searching for Thrombotic Thrombocytopenic Purpura treatment in Atlanta, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Atlanta, Buffalo, Durham and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Thrombotic Thrombocytopenic Purpura. All study-related care is provided at no cost to participants.

Local Sites
3 locations in Georgia
Now Enrolling
Up to 77 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Thrombotic Thrombocytopenic Purpura?

Potential Benefits

  • โœ“Access to new treatment approaches before public availability
  • โœ“Close monitoring by experienced medical professionals
  • โœ“Study-related care provided at no cost
  • โœ“Contribute to medical research for Thrombotic Thrombocytopenic Purpura

What to Expect

  • โ†’Initial screening to determine eligibility
  • โ†’Regular check-ups and monitoring visits
  • โ†’Possible compensation for time and travel
  • โ†’You can withdraw at any time

Frequently Asked Questions About This Thrombotic Thrombocytopenic Purpura Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT04683003. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.